Navigation Links
Celiac disease vaccine shows promising results in Phase I trial
Date:5/9/2011

The world's first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

The Phase I trial undertaken in Melbourne, Australia, evaluated the safety, tolerability and bioactivity of the vaccine Nexvax2, which has been developed for coeliac disease. Coeliac disease is an autoimmune disease caused by an immune reaction to the gluten protein found in wheat, rye and barley.

The three peptides on which the vaccine is based were identified by Dr Bob Anderson from the Walter and Eliza Hall Institute's Immunology division. The vaccine is being further developed by US biotechnology company ImmusanT, of which Dr Anderson is Chief Scientific and Medical Officer. Dr Anderson presented the Phase I trial results on Sunday at the Digestive Disease Week symposium in Chicago, Illinois, US.

"Nexvax2 aims to desensitise patients to the three specific peptides in gluten that we have previously identified as 'toxic' to people with coeliac disease," Dr Anderson said. "Our Phase I study showed that Nexvax2 was safe to use and well tolerated, and importantly, that it had the desired biological response in patients with coeliac disease."

Up to one per cent of the global population is affected by coeliac disease, which is currently only treatable by eliminating gluten from the diet. In people with coeliac disease, immune cells react to gluten and trigger an immune response that damages the lining of the small intestine and inhibits its ability to absorb nutrients from food.

Dr Anderson said the vaccine would be suitable for treating the approximately 90 per cent of coeliac disease patients with the DQ2 genetic form of disease.

"In our Phase I trial, we saw a Nexvax2-specific T-cell response that confirms the desired bioactivity in HLA-DQ2 genotype patients," Dr Anderson said. "We expect the vaccine to enter Phase II trials within the next 10 months, and hope to demonstrate a dramatic reduction in the body's rejection of dietary gluten so patients can resume a normal diet and return to good health."

The Phase I study evaluated the effect of weekly injections of Nexvax2 over three weeks in coeliac patients on a strict gluten-free diet. At the highest doses, some patients had gastrointestinal symptoms similar to what they'd experience after eating gluten products. This suggests the vaccine uses the correct peptides for eventually being able to tolerate gluten.

Dr Anderson said the peptides used as part of the vaccine could also be used to improve diagnostic testing of coeliac disease. "Diagnosing coeliac disease can be quite costly, requiring invasive tests and biopsies to confirm the disease," Dr Anderson said. "The results of a population study suggest that a combination of blood and genetic testing could effectively diagnose coeliac disease without these painful and invasive tests, with up to 50 per cent reduction in costs as well, which creates a win-win situation."


'/>"/>

Contact: Ms Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. New and improved gluten-free foods developed for patients with celiac disease
2. New book from the AGA empowers celiac disease patients to get healthy
3. UM School of Medicine Center for Celiac Research finds rate of celiac disease is growing
4. Quest for genes involved in celiac disease
5. Hidden infections crucial to understanding, controlling disease outbreaks
6. Iron-moving malfunction may underlie neurodegenerative diseases, aging
7. LIAI launches new division to look at novel approaches to heart disease and inflammation
8. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
9. World leaders in infectious diseases convene to discuss emerging global viruses
10. Form of Crohns disease traced to disabled gut cells
11. LSUHSC awarded patent for compound inhibiting cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celiac disease vaccine shows promising results in Phase I trial
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... June 23, 2017 , ... RURO, Inc., a ... of LimitLIS®, its rapidly growing Laboratory Information System. , LimitLIS® version 3 is ... integrity, and provide more customization options. Each of these has been “under the ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model Aeronautics ... Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching a ... competition, and success through a STEM-based education platform. , Much like the program ...
(Date:6/22/2017)... ... , ... Building on the success of the inaugural RAADfest last year, RAADfest ... developments in radical life extension. RAADfest combines cutting edge science presented for a lay ... development, making it the largest most comprehensive and inclusive super longevity event in the ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
Breaking Biology Technology: